← Back to Clinical Trials
Recruiting NCT06692335

NCT06692335 HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06692335
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Uterine Fibroids (UF)
Study Type INTERVENTIONAL
Enrollment 112 participants
Start Date 2025-02-06
Primary Completion 2027-06-13

Trial Parameters

Condition Uterine Fibroids (UF)
Sponsor Chinese University of Hong Kong
Study Type INTERVENTIONAL
Phase N/A
Enrollment 112
Sex FEMALE
Min Age 18 Years
Max Age 50 Years
Start Date 2025-02-06
Completion 2027-06-13
Interventions
High-Intensity Focused Ultrasound (HIFU)myomectomy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to learn if High-Intensity Focused Ultrasound (HIFU) is as effective as myomectomy for treating symptomatic uterine fibroids in women aged 18 to 50. The main questions it aims to answer are: Is HIFU as effective as myomectomy in improving quality of life for women with uterine fibroids? How do the recovery times and complications compare between HIFU and myomectomy? Researchers will compare the outcomes of women receiving HIFU treatment to those undergoing myomectomy to see if HIFU offers similar or better results with fewer complications. Participants will: Undergo an initial medical assessment, including ultrasounds and blood tests. Receive either HIFU treatment or myomectomy based on random assignment. Complete questionnaires about their symptoms and quality of life before treatment and at follow-up visits (3 and 6 months post-treatment). Be monitored for any complications and recovery progress during follow-up.

Eligibility Criteria

Inclusion Criteria: * Age 18 - 50 years-old * Pre or peri menopausal with FSH less than 25 mIU/ml * BMI \< 33 kg/m2 or abdominal wall thickness \< 5 cm * Uterine size ≤18 weeks based on physical exam assessment * Dominant intramural fibroid ≥ 3cm and ≤ 10cm on imaging * Symptomatic fibroids cause menorrhagia, pressure, or pelvic pain * Willing and able to give informed consent Exclusion Criteria: * Patient with other pelvic mass indicated by history or magnetic resonance imaging (MRI) such as endometriosis, abnormal adnexal mass, ovarian tumor, acute or chronic pelvic inflammatory disease * Morbid obesity * Inability to lie in a prone position for more than 2 hours * Extensive abdominal scar on the acoustic channel * Women with pregnancy, lactation or menopause * Uterine premalignant or malignant pathologies or pathology other than uterine fibroid cannot be ruled out through detailed clinical assessment and investigation including MRI * Rapid growth of fibroids, defined as a doubling i

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology